Investors seeking exposure to cutting-edge life sciences innovations will have a direct line to management teams at the upcoming Life Sciences Virtual Investor Forum, hosted by Virtual Investor Conferences on September 17, 2026. The online event, with B2i Digital, Inc. as the Official Marketing Partner, will showcase seven companies spanning photothermal cancer therapy, cannabinoid-based formulations, precision drug delivery, novel antibiotics, monoclonal antibodies, Focal Adhesion Kinase inhibitors, and FDA-cleared respiratory imaging.
The forum matters because it provides a real-time pulse on therapeutic areas that are attracting significant research and investment. For retail and institutional investors alike, the 30-minute live presentations and Q&A sessions offer a rare chance to hear directly from executives about pipeline progress, clinical milestones, and strategic priorities—insights that can inform investment decisions beyond what static filings provide.
“Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind,” said David Shapiro, Chief Executive Officer of B2i Digital, Inc.
The lineup includes Sona Nanotech Inc., which is advancing a photothermal cancer therapy built on gold nanorods; Raphael Pharmaceutical, focused on cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease; Amplia Therapeutics Ltd., developing Focal Adhesion Kinase inhibitors for cancer and fibrosis; Adaptin Bio, Inc., with precision drug delivery technologies targeting tissues including behind the blood-brain barrier; Acurx Pharmaceuticals, Inc., developing a new class of antibiotics for infections caused by priority pathogens; CytoDyn Inc., studying a humanized monoclonal antibody in solid-tumor oncology; and 4DMedical Ltd., offering FDA-cleared four-dimensional respiratory imaging.
Each company will present live, with sessions scheduled from 11:00 AM to 4:00 PM ET. Replays will be available on the B2i Digital and OTC Markets YouTube channels. Investors can register at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC and view event details and presenting company profiles at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum.
The forum’s significance extends beyond individual company updates. By aggregating companies from multiple exchanges—including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets—Virtual Investor Conferences facilitates cross-border investment discovery. For early-stage biotechs, the exposure can be catalytic, potentially leading to increased analyst coverage, partnership discussions, or capital raising opportunities. For investors, it’s a concentrated look at sectors where scientific breakthroughs often translate into outsized returns.
B2i Digital’s role as marketing partner amplifies the event’s reach through a media network spanning 800+ outlets, 1.7 million+ social media followers, and 70,000 opt-in email subscribers. That visibility can help smaller companies attract the attention of a broader investor base, leveling the playing field against larger peers. As the life sciences sector continues to innovate rapidly, forums like this serve as a critical bridge between discovery and capital, making the September 17 event a notable date for anyone tracking the next wave of medical advancements.
